Skip to main content
. Author manuscript; available in PMC: 2014 Jul 1.
Published in final edited form as: Curr Cancer Drug Targets. 2013 Jul;13(6):640–650. doi: 10.2174/15680096113139990039

Fig. (5). RNA interference of ATG5 did not affect WA-mediated inhibition of cell viability.

Fig. (5)

A, Immunoblot for Atg5–12 using lysates from MDA-MB-231 and MCF-7 cells transiently transfected with a control siRNA- or Atg5-specific siRNA. B, Immunoblot for LC3B using lysates from MDA-MB-231 and MCF-7 cells transiently transfected with a control siRNA or Atg5-targeted siRNA and treated for 12 hours with DMSO or 2 µM of WA. C, Viability of MDA-MB-231 and MCF-7 cells transiently transfected with a control siRNA or Atg5-targeted siRNA and treated for 12 hours with DMSO or 2 µM of WA. Cell viability was determined by trypan blue dye exclusion assay. Results are shown as mean ± SD (n=3). aSignificantly different (P<0.05) compared with DMSO-treated control by one way ANOVA followed by Bonferroni’s multiple comparison test. D, Immunoblot for PARP using lysates from MDA-MB-231 and MCF-7 cells transiently transfected with a control siRNA or Atg5-targeted siRNA and treated for 12 hours with DMSO or 2 µM of WA. Similar results were obtained from replicate experiments.